Equillium (EQ) Cash from Operations (2018 - 2026)
Equillium (EQ) posted quarterly Cash from Operations of 4301000.0 for Q1 2026, up 47.35% year-over-year from 2918905.79 in Q1 2025, and down 37.28% quarter-over-quarter from 3133000.0 in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Cash from Operations (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Cash from Operations for 9 consecutive years, with 4301000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 47.35% year-over-year to 4301000.0; the TTM figure through Mar 2026 stood at 18878000.0 (down 2.63% YoY), while the FY2025 annual figure was 22746000.0, down 19.55% from the prior year.
- Cash from Operations fell to 4301000.0 in Q1 2026 per EQ's latest filing, from 3133000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 27725000.0 in Q4 2022 and bottomed at 13065000.0 in Q3 2022.
- Historically, Cash from Operations has averaged 4505235.29 across 5 years, with a median of 6215000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations jumped 373.61% — and 2025, when it tumbled 512.74%.
- Equillium's Cash from Operations stood at 27725000.0 in 2022, then sank by 120.43% to 5664000.0 in 2023, then surged by 41.75% to 3299000.0 in 2024, then gained by 5.03% to 3133000.0 in 2025, then plunged by 37.28% to 4301000.0 in 2026.
- Business Quant data shows EQ's Cash from Operations at 4301000.0 in Q1 2026, 3133000.0 in Q4 2025, and 8431000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | -4.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.11 Mn |
| Mar 31, 2026 | -4.30 Mn |
| Dec 31, 2025 | -3.13 Mn |
| Sep 30, 2025 | -8.43 Mn |
| Jun 30, 2025 | -3.01 Mn |
| Mar 31, 2025 | -8.17 Mn |
| Dec 31, 2024 | -3.30 Mn |
| Sep 30, 2024 | -7.66 Mn |
| Jun 30, 2024 | 730,000.00 |
| Mar 31, 2024 | -8.80 Mn |
| Dec 31, 2023 | -5.66 Mn |
| Sep 30, 2023 | -1.91 Mn |
| Jun 30, 2023 | -6.22 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Dec 31, 2022 | 27.73 Mn |
| Sep 30, 2022 | -13.07 Mn |
| Jun 30, 2022 | -11.26 Mn |
| Mar 31, 2022 | -12.13 Mn |
| Dec 31, 2021 | -10.13 Mn |
| Sep 30, 2021 | -7.01 Mn |